The impact of red blood cell transfusion on mortality and treatment efficacy in patients treated with radiation: A systematic review

Clinical and Translational Radiation Oncology

Lakshman Vasanthamohan¹  David D'Souza²  David Palma³  Ziad Solh⁴  Max Deschner⁴  Sondos Zayed⁵  Alejandro Lazo-Langner⁶  R. Gabriel Boldt⁶  Syed Omar Gilani⁶ 

[1]Corresponding author at: Victoria Hospital, 800 Commissioners Road East, Rm. E6-117, London, Ontario N6A 5A5, Canada.

[2]Department of Epidemiology and Biostatistics, Western University, London, ON, Canada

[3]Department of Medicine, Division of Hematology, Western University, London, ON, Canada

[4]Department of Medicine, Western University, London, ON, Canada

[5]Department of Oncology, Lakeridge Health, Oshawa, ON, Canada

[6]Department of Radiation Oncology, Western University, London, ON, Canada

关键词: Red blood cell transfusion;    Hemoglobin;    Radiation therapy;    Radiation oncology;   

DOI  :  

来源: DOAJ

【 摘 要 】

Introduction: Packed red blood cell (RBC) transfusion is frequently used in patients undergoing radiotherapy (RT) because retrospective data suggest that anemic patients may respond sub-optimally to RT. No high-quality evidence currently exists to guide transfusion practices and establish hemoglobin (Hb) transfusion thresholds for this patient population, and practice varies significantly across centers. This systematic review investigated whether maintaining higher Hb via transfusion in radiation oncology patients leads to improved outcomes. Methods: We performed a literature search of studies comparing RBC transfusion thresholds in radiation oncology patients. Included studies assessed patients receiving RT for malignancy of any diagnosis or stage. Excluded studies did not evaluate Hb or transfusion as an intervention or outcome. The primary outcome was overall survival. Secondary outcomes included locoregional control, number of transfusions and adverse events. Results: One study met inclusion criteria. The study pooled results from two randomized controlled trials that stratified anemic patients with head and neck squamous cell carcinoma to RBC transfusion versus no transfusion. The study found no significant differences in overall survival or locoregional control after five years, despite increased Hb levels in the transfused group. We conducted a narrative review by extracting data from 10 non-comparative studies involving transfusion in patients receiving RT. Results demonstrated no consistent conclusions regarding whether transfusions improve or worsen outcomes. Conclusions: There is a lack of data on the effects of RBC transfusion on outcomes in patients undergoing RT. Well-designed prospective studies are needed in this area.

【 授权许可】

Unknown